SEC Form 4 · accession 0001337252-26-000005
Cytek Biosciences, Inc. · CTKB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001831915
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2026 | M | 6,107 | — | A | 28,499 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 18, 2026 | M | 6,107 | D | — | — | Common Stock | 6,107 | 44,790 | D |
Explanation of responses
- F1Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter.